Shopping Cart 0
Cart Subtotal
AED 0

VolitionRX Ltd (VNRX) - Medical Equipment - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of various conditions including colorectal cancer, prostate and lung cancers, and inflammatory and other diseases. VolitionRX also conducts research and development, and offers clinical trial services. The company has collaboration with hospital, medical center, universities and research institute. It operates in Belgium, Singapore, the UK and the US. VolitionRX is headquartered in Singapore City, Singapore.

VolitionRX Ltd (VNRX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

VolitionRX Ltd, Medical Equipment, Deal Details 11

Partnerships 11

VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11

VolitionRx Enters into Distribution Agreement with Active Motif 12

VolitionRx Enters into Co-Development Agreement with University of Oxford 13

VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14

VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15

Equity Offering 16

VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16

VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17

VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18

VolitionRX Raises USD8.4 Million in Public Offering of Shares 19

VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24

VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25

VolitionRx Raises USD14.1 Million in Public Offering of Shares 27

VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29

VolitionRx Completes Private Placement Of Shares For USD 3 Million 31

VolitionRX Completes Private Placement Of Shares For USD 0.6 Million 32

VolitionRX Completes Private Placement Of Shares For USD 0.4 Million 33

VolitionRX Completes Private Placement Of Shares For USD 0.5 Million 34

VolitionRX Completes Private Placement Of Shares For USD 1 Million 35

VolitionRX Completes Private Placement Of Units For USD 1.2 Million 36

Acquisition 37

ValiRx Divests Its Stake In VolitionRx For USD 0.6 Million 37

VolitionRX Ltd-Key Competitors 38

VolitionRX Ltd-Key Employees 39

VolitionRX Ltd-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Strategy And Business Planning 41

Sep 19, 2017: VolitionRx Announces its European Colorectal Cancer Strategy 41

Financial Announcements 42

Aug 13, 2018: VolitionRx announces second quarter 2018 financial results and business update 42

May 10, 2018: VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update 44

Nov 09, 2017: VolitionRx Announces Third Quarter 2017 Financial Results and Business Update 45

Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 47

May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 48

Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 49

Corporate Communications 50

Mar 07, 2018: VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board 50

Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 51

Product News 52

Feb 26, 2018: VolitionRx Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer 52

Feb 05, 2018: VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark 54

Sep 14, 2017: Volition Granted Four Additional Patents 55

Jun 30, 2017: Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress 56

May 18, 2017: A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q assays 57

Other Significant Developments 58

May 09, 2018: VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits 58

Mar 01, 2018: VolitionRX Announces Full Fiscal Year 2017 Financial Results and Business Update 59

Sep 22, 2017: VolitionRx Announces the Initial Sale of its New Nu.Q Research Kits 61

Sep 21, 2017: VolitionRx Limited Awarded USD 1.5 Million in Non-Dilutive Funding 62

Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 63

Mar 28, 2017: Volition America Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

VolitionRX Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

VolitionRX Ltd, Medical Equipment, Key Facts, 2017 2

VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

VolitionRX Ltd, Deals By Market, 2012 to YTD 2018 9

VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11

VolitionRx Enters into Distribution Agreement with Active Motif 12

VolitionRx Enters into Co-Development Agreement with University of Oxford 13

VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14

VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15

VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16

VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17

VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18

VolitionRX Raises USD8.4 Million in Public Offering of Shares 19

VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24

VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25

VolitionRx Raises USD14.1 Million in Public Offering of Shares 27

VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29

VolitionRx Completes Private Placement Of Shares For USD 3 Million 31

VolitionRX Completes Private Placement Of Shares For USD 0.6 Million 32

VolitionRX Completes Private Placement Of Shares For USD 0.4 Million 33

VolitionRX Completes Private Placement Of Shares For USD 0.5 Million 34

VolitionRX Completes Private Placement Of Shares For USD 1 Million 35

VolitionRX Completes Private Placement Of Units For USD 1.2 Million 36

ValiRx Divests Its Stake In VolitionRx For USD 0.6 Million 37

VolitionRX Ltd, Key Competitors 38

VolitionRX Ltd, Key Employees 39

VolitionRX Ltd, Subsidiaries 40

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

VolitionRX Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

VolitionRX Ltd (VolitionRX) is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of various conditions including colorectal cancer, prostate and lung cancers, and inflammatory and other diseases. VolitionRX also conducts research and development, and offers clinical trial services. The company has collaboration with hospital, medical center, universities and research institute. It operates in Belgium, Singapore, the UK and the US. VolitionRX is headquartered in Singapore City, Singapore.

VolitionRX Ltd (VNRX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

VolitionRX Ltd, Medical Equipment, Deal Details 11

Partnerships 11

VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11

VolitionRx Enters into Distribution Agreement with Active Motif 12

VolitionRx Enters into Co-Development Agreement with University of Oxford 13

VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14

VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15

Equity Offering 16

VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16

VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17

VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18

VolitionRX Raises USD8.4 Million in Public Offering of Shares 19

VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24

VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25

VolitionRx Raises USD14.1 Million in Public Offering of Shares 27

VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29

VolitionRx Completes Private Placement Of Shares For USD 3 Million 31

VolitionRX Completes Private Placement Of Shares For USD 0.6 Million 32

VolitionRX Completes Private Placement Of Shares For USD 0.4 Million 33

VolitionRX Completes Private Placement Of Shares For USD 0.5 Million 34

VolitionRX Completes Private Placement Of Shares For USD 1 Million 35

VolitionRX Completes Private Placement Of Units For USD 1.2 Million 36

Acquisition 37

ValiRx Divests Its Stake In VolitionRx For USD 0.6 Million 37

VolitionRX Ltd-Key Competitors 38

VolitionRX Ltd-Key Employees 39

VolitionRX Ltd-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Strategy And Business Planning 41

Sep 19, 2017: VolitionRx Announces its European Colorectal Cancer Strategy 41

Financial Announcements 42

Aug 13, 2018: VolitionRx announces second quarter 2018 financial results and business update 42

May 10, 2018: VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update 44

Nov 09, 2017: VolitionRx Announces Third Quarter 2017 Financial Results and Business Update 45

Aug 09, 2017: VolitionRx Announces Second Quarter 2017 Financial Results and Business Update 47

May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 48

Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 49

Corporate Communications 50

Mar 07, 2018: VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board 50

Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 51

Product News 52

Feb 26, 2018: VolitionRx Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer 52

Feb 05, 2018: VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark 54

Sep 14, 2017: Volition Granted Four Additional Patents 55

Jun 30, 2017: Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress 56

May 18, 2017: A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q assays 57

Other Significant Developments 58

May 09, 2018: VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits 58

Mar 01, 2018: VolitionRX Announces Full Fiscal Year 2017 Financial Results and Business Update 59

Sep 22, 2017: VolitionRx Announces the Initial Sale of its New Nu.Q Research Kits 61

Sep 21, 2017: VolitionRx Limited Awarded USD 1.5 Million in Non-Dilutive Funding 62

Aug 22, 2017: Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers 63

Mar 28, 2017: Volition America Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

VolitionRX Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

VolitionRX Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

VolitionRX Ltd, Medical Equipment, Key Facts, 2017 2

VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

VolitionRX Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

VolitionRX Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

VolitionRX Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

VolitionRX Ltd, Deals By Market, 2012 to YTD 2018 9

VolitionRX Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

VolitionRx Enters Into Licensing Agreement With Innova Biosciences For Biotin Technology 11

VolitionRx Enters into Distribution Agreement with Active Motif 12

VolitionRx Enters into Co-Development Agreement with University of Oxford 13

VolitionRx Enters Into Distribution Agreement With Active Motif For NuQ Product Line 14

VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based Biomarkers For Cancer 15

VolitionRx Plans to Raise up to USD25.6 Million in Public Offering of Shares and Warrants 16

VolitionRx Plans to Raise up to USD100 Million in Public Offering of Securities 17

VolitionRx to Raise USD6.6 Million in Private Placement of Shares 18

VolitionRX Raises USD8.4 Million in Public Offering of Shares 19

VolitionRX Raises USD0.5 Million in Private Placement of Shares upon Exercise of Warrants 20

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 21

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 22

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 23

VolitionRX Raises Funds through Private Placement of Shares upon Exercise of Warrants 24

VolitionRX Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 25

VolitionRx Raises USD14.1 Million in Public Offering of Shares 27

VolitionRx Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD10.6 Million 29

VolitionRx Completes Private Placement Of Shares For USD 3 Million 31

VolitionRX Completes Private Placement Of Shares For USD 0.6 Million 32

VolitionRX Completes Private Placement Of Shares For USD 0.4 Million 33

VolitionRX Completes Private Placement Of Shares For USD 0.5 Million 34

VolitionRX Completes Private Placement Of Shares For USD 1 Million 35

VolitionRX Completes Private Placement Of Units For USD 1.2 Million 36

ValiRx Divests Its Stake In VolitionRx For USD 0.6 Million 37

VolitionRX Ltd, Key Competitors 38

VolitionRX Ltd, Key Employees 39

VolitionRX Ltd, Subsidiaries 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

VolitionRX Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

chat_bubbleLet's Chat